logo
Share SHARE
FONT-SIZE Plus   Neg

XenoPort Gets U.S. Patent Directed To Composition And Formulations Of XP23829

XenoPort Inc. (XNPT) said it was awarded U.S. Patent 8,148,414 for "Prodrugs of Methyl Hydrogen Fumarate, Pharmaceutical Compositions Thereof, and Methods of Use." Subject to potential Hatch-Waxman patent term extensions, the term of the patent extends until 2029.

The patent is directed to the XP23829 compound, analogs thereof and formulations thereof, XenoPort added. A related U.S. patent application directed to therapeutic uses of XP23829 is currently pending. XP23829 is a prodrug of methyl hydrogen fumarate, also called as monomethyl fumarate or MMF. In cell- and animal-based models, MMF has been shown to exhibit immuno-modulatory properties and inhibit damage from oxidative stress.

XenoPort, which owns all rights to XP23829, plans to file an Investigational New Drug Application for XP23829 for the treatment of relapsing remitting MS with the U.S. Food and Drug Administration in the second quarter of 2012 and expects to initiate human clinical trials later this year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
About nine-tenths of the world's sea birds are likely to have consumed pieces of plastic which continue to remain in their guts, a study shows. Automakers reported some mixed U.S. sales for August, marked by fewer working days and a delayed Labor Day, even as the month was largely bullish, spurred by lower interest rates, cheaper gas, and some strong employment data that buoyed consumer confidence. Bank of Nova Scotia or otherwise known as Scotiabank, Friday reported lower net profit for the third quarter, in the absence of a year-ago gain. Earnings per share, however, came in line with the Street view. Further, the company said it raised its quarterly dividend by 2 cents.
comments powered by Disqus
Follow RTT